Tibor Moskovits

Hematology

240 E 38th St
New York, NY 10016

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4 publications

Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis.

Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis.

Journal: Leukemia & lymphoma

Published: January 05, 2025

Impaired Humoral Immunity to SARS-CoV-2 Vaccination in Non-Hodgkin Lymphoma and CLL Patients.

Impaired Humoral Immunity to SARS-CoV-2 Vaccination in Non-Hodgkin Lymphoma and CLL Patients.

Journal: medRxiv : the preprint server for health sciences

Published: June 08, 2021

Microbial dysbiosis is associated with aggressive histology and adverse clinical outcome in B-cell non-Hodgkin lymphoma.

Microbial dysbiosis is associated with aggressive histology and adverse clinical outcome in B-cell non-Hodgkin lymphoma.

Journal: Blood advances

Published: August 05, 2020

Development of highly aggressive mantle cell lymphoma after sofosbuvir treatment of hepatitis C.

Development of highly aggressive mantle cell lymphoma after sofosbuvir treatment of hepatitis C.

Journal: Blood cancer journal

Published: March 12, 2016

Showing 1-4 of 4

Last Updated: 09/26/2026